In connection with the transaction, structured as a reverse merger, Alynx issued approximately 52.9 million new shares of its common stock, and approximately 3.7 million new shares of its preferred stock (convertible into approximately 56.9 million shares of its common stock, subject to specified conditions). Also in connection with the merger, Alynx repurchased and canceled 20 million shares of its outstanding common stock.
The shares issued in the merger were issued pursuant to a private placement and are not presently eligible for resale to the public.